Loading…
Life-sciences and diagnostics company (renamed from PerkinElmer in 2023) providing reagents, instruments and software for research and diagnostics.
Life-sciences and diagnostics company (renamed from PerkinElmer in 2023) providing reagents, instruments and software for research and diagnostics.
Sells instruments once and then keeps selling the reagents, assay kits and consumables they need, a pattern that repeats across research labs and diagnostic laboratories, with a software unit alongside. It rebranded from PerkinElmer in 2023 after selling its food and environmental testing business, having bought BioLegend in 2021 to enlarge its research reagents side.
Moat: narrow (installed base, switching costs, brand). Established newborn-screening and reagent franchises with recurring, workflow-embedded consumables.
Headquarters: Waltham, Massachusetts, USA · Founded: 1937 · Employees: 11,000
Size Revvity (RVTY) is a United States Health Care company (Medical Specialties) with a market value of $17.3B, the 541st largest of 3,117 United States companies the cockpit tracks. Shares closed at $155.11 on 6 Nov 2026.
Performance Over six months the shares gained 53.6%, against +27.4% for the median peer and -1.1% for the United States market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue grew 4.6% over the last twelve months (peer median +6.2%); the operating margin is 15.4% (peer median 17.0%).
Valuation It trades at 26.7× forward earnings against a peer median of 24.6× (8th most expensive of 20).
Price implies For today's price to make sense, revenue must grow about 27% a year for seven years (Req g). Recent delivered growth is -5%, so the hurdle is +33 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 5.8 points below its cost of capital (9.6% WACC).
Credit Revvity has 4 bonds outstanding ($2.25B), rated BBB by the agencies and trading like BBB at a weighted spread of 78 bp.
Short interest Short interest is 5.7% of the free float (15 Oct 2026).
Next results Next results expected around 4 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $2.94B | $2.86B | $2.76B | $2.75B | $3.31B |
| Revenue growth | — | +4% | 0% | -17% | — |
| Gross profit | $1.41B | $1.37B | $1.32B | $1.32B | $1.76B |
| EBITDA | $867M | $833M | $838M | $831M | $1.21B |
| Net income | $254M | $242M | $296M | -$118M | $569M |
| Free cash flow | $588M | $507M | $542M | $9.90M | $594M |
| Capital expenditure | $65.4M | $73.5M | $86.6M | $1.30B | $85.6M |
| Total debt | $2.77B | $3.40B | $3.33B | $4.07B | $4.60B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Revvity RVTY | $17.3B | +54% | +5% | 15% | 26.7× | 27.3% |
| Thermo Fisher Scientific TMO | $257B | +50% | +8% | 19% | 25.8× | 20.9% |
| Danaher DHR | $162B | +35% | +6% | 21% | 25.3× | 20.5% |
| Bio-Rad Laboratories BIO | $10.3B | +50% | +1% | 9% | 35.7× | 26.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | RVTY | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.9% | +15.3% | 4th lowest of 21 |
| 6-month return | +53.6% | +27.4% | 5th highest of 21 |
| Distance from 52-week high | -9.7% | -12.0% | 10th highest of 21 |
| Revenue growth (TTM) | +4.6% | +6.2% | 9th lowest of 21 |
| Operating margin | 15.4% | 17.0% | 8th lowest of 21 |
| Forward P/E | 26.7× | 24.6× | 8th most expensive of 20 |
| Growth the price implies (Req g, 7 yrs) | 27.3% | 11.1% | 4th most demanding of 18 |
| Growth delivered (Del g) | -5.5% | +9.2% | lowest of 18 |
| Hurdle (Req g minus delivered) | +32.7 pp | +1.1 pp | most demanding of 18 |
| ROIC minus cost of capital | -5.8 pp | +2.0 pp | 3rd lowest of 21 |
| EV / EBITDA | 22.5× | 14.0× | 5th most expensive of 17 |
| Net debt / EBITDA | 2.5× | 1.4× | 4th most indebted of 17 |
| Bond spread | 78 bp | 107 bp | 2nd tightest of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Revvity RVTY | United States | $17.3B | +54% | +5% | 15% | 26.7× | 27.3% | -5.5% |
| Coloplast A/S COLO-B.CO | Denmark | $17.7B | +26% | +4% | 25% | 19.9× | -1.8% | +8.3% |
| Sartorius SRT.DE | Germany | $20.0B | +34% | +4% | 18% | 42.6× | 24.9% | +8.7% |
| Zimmer Biomet ZBH | United States | $20.1B | +29% | +7% | 16% | 12.0× | -1.4% | +3.2% |
| Shanghai United Imaging Healthcare 688271.SS | China | $14.8B | +9% | +27% | 9% | 46.9× | n/a | n/a |
| Guardant Health GH | United States | $20.2B | +58% | +43% | -40% | n/a | n/a | n/a |
| Sonova SOON.SW | Switzerland | $20.3B | +62% | -7% | 21% | 25.6× | 7.1% | +6.7% |
| Straumann STMN.SW | Switzerland | $20.4B | +25% | +2% | 21% | 31.9× | 15.2% | +12.8% |
| Lenskart Solutions LENSKART.NS | India | $13.4B | +49% | +35% | 10% | 137.4× | 52.8% | +33.5% |
| Baxter International BAX | United States | $13.3B | +43% | +5% | 6% | 12.6× | 12.7% | -0.7% |
| Glaukos GKOS | United States | $13.3B | +68% | +47% | -9% | 155.4× | n/a | n/a |
| Smith & Nephew SN..L | United Kingdom | $13.1B | +5% | +2% | 17% | 14.4× | 11.1% | +5.6% |
| Terumo 4543.T | Japan | $23.4B | +25% | +14% | 17% | 24.6× | 8.7% | +13.0% |
| Penumbra PEN | United States | $12.6B | -1% | +17% | 12% | 54.9× | 30.1% | +20.2% |
| bioMerieux BIM.PA | France | $12.4B | +29% | -3% | 15% | 20.9× | 8.9% | +5.5% |
| Steris STE | United States | $24.6B | +22% | +8% | 20% | 21.4× | 13.7% | +13.8% |
| Olympus 7733.T | Japan | $12.2B | +13% | +8% | 16% | 18.0× | -1.5% | +6.7% |
| Sartorius Stedim Biotech DIM.PA | France | $24.7B | +38% | +4% | 19% | 45.5× | 33.1% | +9.2% |
| Cooper Companies (The) COO | United States | $11.9B | +4% | +5% | 19% | 13.8× | 9.4% | +11.0% |
| Align Technology ALGN | United States | $11.8B | -2% | +4% | 19% | 13.9× | 11.4% | +10.3% |
| Demant A/S DEMANT.CO | Denmark | $11.6B | +62% | +10% | 18% | 25.7× | 6.8% | +9.8% |
Revvity has 4 bonds outstanding with $2.25B face value. The agencies rate it BBB; its bonds trade like BBB. Weighted yield 5.34%, a spread of 78 bp over government bonds.